Clinical Trial Update: Continuation With Vortioxetine in Child and Adolescent Patients With Major Depressive Disorder (MDD) From 7 to 17 Years of Age [Phase 3]

View source ↗

Summary

Phase 3 continuation study of vortioxetine in children and adolescents (7-17) with major depressive disorder has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Major Depressive Disorder

Drugs mentioned

• Vortioxetine (vortioxetine)

Snippet

Sponsor: H. Lundbeck A/S | Conditions: Depressive Disorder, Major | Phase 3 | Status: COMPLETED